Alkermes Plc CFO Sells $310,100 in Stock (ALKS)
Alkermes Plc (NASDAQ:ALKS) CFO James M. Frates sold 7,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $44.30, for a total value of $310,100.00. Following the sale, the chief financial officer now directly owns 42,904 shares of the company’s stock, valued at approximately $1,900,647. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of Alkermes Plc (NASDAQ:ALKS) traded up 1.64% during mid-day trading on Thursday, hitting $45.21. The stock had a trading volume of 538,469 shares. Alkermes Plc has a 52-week low of $26.47 and a 52-week high of $54.25. The stock’s 50-day moving average is $44.80 and its 200-day moving average is $44.33. The company’s market cap is $6.534 billion.
Alkermes Plc (NASDAQ:ALKS) last released its earnings data on Wednesday, April 30th. The company reported $0.11 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.10 by $0.01. The company had revenue of $130.21 million for the quarter, compared to the consensus estimate of $135.79 million. During the same quarter last year, the company posted $0.40 earnings per share. Alkermes Plc’s revenue was down 20.3% compared to the same quarter last year. Analysts expect that Alkermes Plc will post $0.49 EPS for the current fiscal year.
A number of research firms have recently commented on ALKS. Analysts at Jefferies Group initiated coverage on shares of Alkermes Plc in a research note on Friday, May 16th. They set a “buy” rating and a $53.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Alkermes Plc in a research note on Friday, May 2nd. They now have a $50.00 price target on the stock. Finally, analysts at Zacks downgraded shares of Alkermes Plc from an “outperform” rating to a “neutral” rating in a research note on Wednesday, April 16th. They now have a $45.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Alkermes Plc presently has an average rating of “Hold” and an average price target of $47.00.
Alkermes Public Limited Company is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (NASDAQ:ALKS) disorders such as addiction, schizophrenia and depression.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.